X
RARE icon

Xponance’s Ultragenyx Pharmaceutical RARE Stock Holding History

Xponance’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Sell
10,051
-6,415
-39% -$159K ﹤0.01% 1335
2026
Q1 		$345K Buy
16,466
+2,076
+14% +$46.7K ﹤0.01% 1194
2025
Q4 		$331K Buy
14,390
+896
+7% +$29.5K ﹤0.01% 1132
2025
Q3 		$406K Buy
13,494
+406
+3% +$12.2K ﹤0.01% 1041
2025
Q2 		$476K Buy
13,088
+536
+4% +$19.3K ﹤0.01% 973
2025
Q1 		$455K Buy
12,552
+347
+3% +$14.4K ﹤0.01% 965
2024
Q4 		$513K Buy
12,205
+940
+8% +$46.6K ﹤0.01% 942
2024
Q3 		$626K Buy
11,265
+174
+2% +$8.86K 0.01% 867
2024
Q2 		$456K Buy
11,091
+1,279
+13% +$54.6K ﹤0.01% 933
2024
Q1 		$458K Sell
9,812
-350
-3% -$16.5K ﹤0.01% 969
2023
Q4 		$486K Buy
10,162
+648
+7% +$25.1K 0.01% 937
2023
Q3 		$339K Buy
9,514
+53
+0.6% +$2.1K ﹤0.01% 1009
2023
Q2 		$436K Buy
9,461
+1,824
+24% +$84.6K 0.01% 946
2023
Q1 		$306K Sell
7,637
-78
-1% -$3.35K ﹤0.01% 1039
2022
Q4 		$357K Buy
7,715
+1,354
+21% +$53.3K 0.01% 997
2022
Q3 		$263K Sell
6,361
-85
-1% -$4.37K 0.01% 1027
2022
Q2 		$385K Buy
6,446
+750
+13% +$46.2K 0.01% 948
2022
Q1 		$414K Sell
5,696
-22
-0.4% -$1.53K 0.01% 956
2021
Q4 		$481K Buy
5,718
+97
+2% +$7.89K 0.01% 915
2021
Q3 		$507K Sell
5,621
-173
-3% -$15.6K 0.01% 884
2021
Q2 		$552K Buy
+5,794
New +$604K 0.01% 880
2021
Q1 		– Sell
-1,838
Closed -$254K – 1055
2020
Q4 		$254K Buy
+1,838
New +$218K 0.01% 995
2020
Q3 		– Sell
-2,627
Closed -$205K – 1047
2020
Q2 		$205K Buy
+2,627
New +$174K 0.01% 963

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Xponance's RARE Position: Q2 2026 in Review

Xponance reduced its Ultragenyx Pharmaceutical (RARE) stake by 39% in Q2 2026, selling an estimated $159K and leaving 10,051 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #1335.

Xponance first reported a position in RARE in Q2 2020 and has held it in 23 quarters since. The position peaked at $626K in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Xponance held 10,051 shares of Ultragenyx Pharmaceutical worth $336K as of Q2 2026.
  • Xponance sold 6,415 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $159K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1335 holding.
  • Xponance first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and has held it in 23 quarters since.
  • Xponance's Ultragenyx Pharmaceutical position peaked at $626K in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.